Gene delivery vehicle expressing the aptosis-inducing proteins VP2 and/or apoptin
AssigneeLeadd B.V.
InventorsMatheus Hubertus Maria Noteborn, Alexandra Maria Pietersen
Life of this patent
Estimating the term…
Abstract
The invention relates to gene delivery vehicles which comprise nucleic acid molecules encoding apoptosis-inducing proteins VP2 and/or apoptin (VP3) like activity. VP2 and VP3 are viral proteins of the Chicken Anaemia Virus. Also, the invention relates to anti-tumor therapies. Infection of various human tumor cells with the gene delivery vehicles of the invention will result in the induction of apoptosis in tumor cells and much reduced apoptosis, if at all, in normal diploid, non-transformed/non-malignant cells. Also the invention relates to the diagnosis of cancer, and related forms of hyperplasia, metaplasia and dysplasia.
Claims17
A recombinant gene delivery vehicle comprising a nucleic acid molecule encoding a chicken anemia virus protein VP3.
A recombinant gene delivery vehicle comprising a nucleic acid molecule encoding a chicken anemia virus protein VP3, having a modified translation initiation site directly upstream of the ATG-initiation codon of said nucleic acid molecule, wherein said translation initiation site comprises the nucleic acid sequence GCCAAC.
A recombinant gene delivery vehicle comprising a nucleic acid molecule encoding a chicken anemia virus protein VP2.
A recombinant gene delivery vehicle comprising a nucleic acid molecule encoding a chicken anemia virus protein VP2, having a modified translation initiation site directly upstream of the ATG-initiation codon of said nucleic acid molecule, wherein said translation initiation site comprises the nucleic acid sequence GCCAAC.
Dependencies are inferred from the claim text.